Literature DB >> 11168952

Progression of diabetic nephropathy.

P Hovind1, P Rossing, L Tarnow, U M Smidt, H H Parving.   

Abstract

BACKGROUND: Diabetic nephropathy is a major cause of renal failure. The decline in glomerular filtration rate (GFR) is highly variable, ranging from 2 to 20, with a median of 12 mL/min/year. The risk factors of losing filtration power (progression promoters) have not been clearly identified. Furthermore, information on optimal arterial blood pressure, glycemic control, and cholesterol levels are lacking.
METHODS: We measured GFR with (51)Cr-EDTA plasma clearance technique, blood pressure, albuminuria, glycosylated hemoglobin A1c, and serum cholesterol every year for seven years (range 3 to 14 years) in 301 consecutive type 1 diabetic patients with diabetic nephropathy recruited consecutively during 1983 through 1997. Diabetic nephropathy was diagnosed clinically if the following criteria were fulfilled: persistent albuminuria> 200 microg/min, presence of diabetic retinopathy, and no evidence of other kidney or renal tract disease. In total, 271 patients received antihypertensive treatment at the end of the observation period.
RESULTS: Mean arterial blood pressure was 102 +/- 0.4 (SE) mm Hg. The average decline in GFR was 4.0 +/- 0.2 mL/min/year and even lower (1.9 +/- 0.5 mL/min/year) in the 30 persistently normotensive patients, none of whom had ever received antihypertensive treatment (P < 0.01). A multiple linear regression analysis revealed a significant positive correlation between the decline in GFR and mean arterial blood pressure, albuminuria, glycosylated hemoglobin A(1c), and serum cholesterol during follow-up (R(adj)(2) = 0.29, P < or = 0.001). No threshold level for blood pressure, glycosylated hemoglobin A(1c), or serum cholesterol was demonstrated. A two-hit model with mean arterial blood pressure and glycosylated hemoglobin A(1c) below and above the median values (102 mm Hg and 9.2%, respectively) revealed a rate of decline in GFR of only 1.5 mL/min/year in the lowest stratum compared with 6.1 mL/min/year in the highest stratum (P < 0.001).
CONCLUSIONS: The prognosis of diabetic nephropathy has improved during the past decades, predominantly because of effective antihypertensive treatment. Genuine normotensive patients have a slow progression of nephropathy. Several modifiable variables have been identified as progression promoters.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11168952     DOI: 10.1046/j.1523-1755.2001.059002702.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  72 in total

Review 1.  Systolic pressure, diastolic pressure, or pulse pressure as a cardiovascular risk factor in renal disease.

Authors:  José A García-Donaire; Luis M Ruilope
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

Review 2.  Renal protection in hypertensive patients: selection of antihypertensive therapy.

Authors:  René R Wenzel
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  End stage renal disease.

Authors:  Yoshio N Hall; Glenn M Chertow
Journal:  BMJ Clin Evid       Date:  2007-10-17

4.  Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005.

Authors:  P Rossing
Journal:  Diabetologia       Date:  2005-12-09       Impact factor: 10.122

Review 5.  End-stage renal disease.

Authors:  Maaz Ahmed Abbasi; Glenn M Chertow; Yoshio N Hall
Journal:  BMJ Clin Evid       Date:  2010-07-19

Review 6.  Blood pressure control--effects on diabetic nephropathy progression: how low does blood pressure have to be?

Authors:  Christopher A Newton; Philip Raskin
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

Review 7.  The relationship between glucose control and the development and progression of diabetic nephropathy.

Authors:  Carrie A Phillips; Mark E Molitch
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

Review 8.  The choice of antihypertensive drugs in patients with diabetes: angiotensin II and beyond.

Authors:  Kambiz Kalantarinia; Helmy M Siragy
Journal:  Curr Diab Rep       Date:  2002-10       Impact factor: 4.810

9.  Efficacy of pentoxifylline for reduction of proteinuria in type II diabetic patients.

Authors:  Farshid Oliaei; Shirin Hushmand; Soraya Khafri; Mahmoud Baradaran
Journal:  Caspian J Intern Med       Date:  2011

Review 10.  Hypertension management in patients with diabetic nephropathy.

Authors:  Anthony L McCall
Journal:  Curr Hypertens Rep       Date:  2004-08       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.